SEARCH

SEARCH BY CITATION

Abstract

Objective

CCR5 and its ligands (CCL3, CCL4, and CCL5) may play a role in inflammatory cell recruitment into the joint. However, it was recently reported that CCR5 on T cells and neutrophils acts as a decoy receptor for CCL3 and CCL5 to assist in the resolution of inflammation. The aim of this study was to determine whether CCR5 functions as a proinflammatory or antiinflammatory mediator in arthritis, by examining the role of CCR5 in proteoglycan (PG)–induced arthritis (PGIA).

Methods

Arthritis was induced by immunizing wild-type (WT) and CCR5-deficient (CCR5−/−) BALB/c mice with human PG in adjuvant. The onset and severity of PGIA were monitored over time. Met-RANTES was used to block CCR5 in vivo. Arthritis was transferred to SCID mice, using spleen cells from arthritic WT and CCR5−/− mice. The expression of cytokines and chemokines was measured by enzyme-linked immunosorbent assay.

Results

In CCR5−/− mice and WT mice treated with the CCR5 inhibitor Met-RANTES, exacerbated arthritis developed late in the disease course. The increase in arthritis severity in CCR5−/− mice correlated with elevated serum levels of CCL5. However, exacerbated arthritis was not intrinsic to the CCR5−/− lymphoid cells, because the arthritis that developed in SCID mouse recipients was similar to that in WT and CCR5−/− mice. CCR5 expression in the SCID mouse was sufficient to clear CCL5, because serum levels of CCL5 were the same in SCID mouse recipients receiving cells from either WT or CCR5−/− mice.

Conclusion

These data demonstrate that CCR5 is a key player in controlling the resolution of inflammation in experimental arthritis.